4233 related articles for article (PubMed ID: 6205747)
1. Selective extraction by 1-butanol of surface glycoprotein antigens from human melanoma cells.
Liao SK; Smith JW; Kwong PC
Cancer Immunol Immunother; 1984; 17(2):95-9. PubMed ID: 6205747
[TBL] [Abstract][Full Text] [Related]
2. Noncytolytic extraction of cell surface antigens using butanol.
LeGrue SJ
Cancer Metastasis Rev; 1985; 4(3):209-19. PubMed ID: 3907820
[TBL] [Abstract][Full Text] [Related]
3. Phenotyping of 60 cultured human gliomas and 34 other neuroectodermal tumors by means of monoclonal antibodies against glioma, melanoma and HLA-DR antigens.
de Muralt B; de Tribolet N; Diserens AC; Stavrou D; Mach JP; Carrel S
Eur J Cancer Clin Oncol; 1985 Feb; 21(2):207-16. PubMed ID: 2985398
[TBL] [Abstract][Full Text] [Related]
4. Selective release of surface antigens from cultured human melanoma cells following 1-butanol treatment.
Liao SK; Smith JW
Prog Clin Biol Res; 1983; 133():203-7. PubMed ID: 6622493
[No Abstract] [Full Text] [Related]
5. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
[TBL] [Abstract][Full Text] [Related]
6. Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinations.
Mortarini R; Belli F; Parmiani G; Anichini A
Int J Cancer; 1990 Feb; 45(2):334-41. PubMed ID: 1689276
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic dynamics of tumor progression in human malignant melanoma.
Bröcker EB; Suter L; Brüggen J; Ruiter DJ; Macher E; Sorg C
Int J Cancer; 1985 Jul; 36(1):29-35. PubMed ID: 3860479
[TBL] [Abstract][Full Text] [Related]
8. The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines.
Sørensen RB; Junker N; Kirkin A; Voigt H; Svane IM; Becker JC; thor Straten P; Andersen MH
Cancer Immunol Immunother; 2009 May; 58(5):665-75. PubMed ID: 18828018
[TBL] [Abstract][Full Text] [Related]
9. Modulation by cytokines of HLA antigens, intercellular adhesion molecule 1 and high molecular weight melanoma associated antigen expression and of immune lysis of clones derived from the melanoma cell line MeM 50-10.
Maio M; Gulwani B; Tombesi S; Ferrone S
Cancer Immunol Immunother; 1989; 30(1):34-42. PubMed ID: 2513111
[TBL] [Abstract][Full Text] [Related]
10. Antigenic phenotype of pigment cell lesions: a study of melanoma, its precursor lesions and heterogeneity in metastatic melanoma.
Ernstoff MS; Duray P; Stenn K; Kirkwood JM
J Invest Dermatol; 1985 May; 84(5):430-2. PubMed ID: 3889169
[TBL] [Abstract][Full Text] [Related]
11. Changes in HLA-DR antigen expression on cultured human melanoma cells during theophylline treatment.
Liao SK; Kwong PC; Dent PB; Jerry LM
Tissue Antigens; 1982 Aug; 20(2):147-51. PubMed ID: 6958088
[TBL] [Abstract][Full Text] [Related]
12. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.
Robbins PF; El-Gamil M; Li YF; Zeng G; Dudley M; Rosenberg SA
J Immunol; 2002 Nov; 169(10):6036-47. PubMed ID: 12421991
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens.
Albino AP; Lloyd KO; Houghton AN; Oettgen HF; Old LJ
J Exp Med; 1981 Dec; 154(6):1764-78. PubMed ID: 6976407
[TBL] [Abstract][Full Text] [Related]
14. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions.
Taramelli D; Fossati G; Mazzocchi A; Delia D; Ferrone S; Parmiani G
Cancer Res; 1986 Jan; 46(1):433-9. PubMed ID: 3079589
[TBL] [Abstract][Full Text] [Related]
15. HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes.
Guerry D; Alexander MA; Herlyn MF; Zehngebot LM; Mitchell KF; Zmijewski CM; Lusk EJ
J Clin Invest; 1984 Jan; 73(1):267-71. PubMed ID: 6606651
[TBL] [Abstract][Full Text] [Related]
16. Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon.
Houghton AN; Thomson TM; Gross D; Oettgen HF; Old LJ
J Exp Med; 1984 Jul; 160(1):255-69. PubMed ID: 6204001
[TBL] [Abstract][Full Text] [Related]
17. Functional consequence of variation in melanoma antigen expression.
Zehngebot LM; Alexander MA; Guerry D; Cines DB; Mitchell K; Herlyn M
Cancer Immunol Immunother; 1983; 16(1):30-4. PubMed ID: 6605801
[TBL] [Abstract][Full Text] [Related]
18. Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells.
Parmiani G; Fossati G; Taramelli D; Anichini A; Balsari A; Gambacorti-Passerini C; Sciorelli G; Cascinelli N
Cancer Metastasis Rev; 1985; 4(1):7-26. PubMed ID: 3888384
[TBL] [Abstract][Full Text] [Related]
19. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.
Parkhurst MR; DePan C; Riley JP; Rosenberg SA; Shu S
J Immunol; 2003 May; 170(10):5317-25. PubMed ID: 12734382
[TBL] [Abstract][Full Text] [Related]
20. Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes.
Holzmann B; Bröcker EB; Lehmann JM; Ruiter DJ; Sorg C; Riethmüller G; Johnson JP
Int J Cancer; 1987 Apr; 39(4):466-71. PubMed ID: 3104215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
